Onartuzumab in lung cancer: The fall of Icarus?

Expert Review of Anticancer Therapy

Volumn 15, Issue 5, 2015, Pages 487-489

  Rolfo, Christian ^a,b   Van Der Steen, Nele ^b   Pauwels, Patrick ^a,b   Cappuzzo, Federico ^c  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

c MET; non small cell lung cancer; ornatuzumab; Phase I; trial design

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; ONARTUZUMAB; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

DRUG EFFICACY; HUMAN; LUNG BIOPSY; LUNG PARENCHYMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DESIGN; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE;

EID: 84928606138     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1031219     Document Type: Review

References (16)

1. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316: 1039-43
2. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
3. Guo B, Cen H, Tan X, et al. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: A meta-analysis of published literatures. PLoS One 2014;9:e99399
4. Tsuta K, Kozu Y, Mimae T, et al. c-MET/ phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012;7:331-9
5. Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009;124:1778-84
6. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with Erlotinib in patients with advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2013;31:4105-14
7. Spigel DR, Edelman MJ, Mok T, et al. Treatment rationale study design for the MetLung trial: A randomized, double-blind phase III study of Onartuzumab (MetMAb) in combination with Erlotinib versus Erlotinib alone in patients who have received standard chemotherapy for Stage IIIB or IV Met-Po. Clin Lung Cancer 2012;13:500-4
8. Koeppen H, Yu W, Zha J, et al. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib {+/-} Onartuzumab in Advanced Non-Small-Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clin Cancer Res 2014;20:4488-98
9. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013;110:E2987-96
10. Yano S, Takeuchi S, Nakagawa T, et al. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci 2012;103:1189-94
11. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87
12. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103:645-61
13. Spigel DR, Edelman MJ, O'Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase 3 randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014;32:5s(Suppl; abstr 8000)
14. Reznik TE, Sang Y, Ma Y, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 2008;6: 139-50
15. Guo A, Villén J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008;105:692-7
16. Breindel JL, Haskins JW, Cowell EP, et al. EGF Receptor activates MET through MAP kinases to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res 2013;73(16):5053-65